Moleculin Biotech’s Strategic Advancements and Potential in Oncology: Buy Rating Justified by Key Partnerships and Promising Trials
I'm PortAI, I can summarize articles.
Moleculin Biotech has received a Buy rating from analyst Sara Nik of H.C. Wainwright, with a price target of $4.00. This rating is supported by strategic advancements in oncology, including a partnership with the University of North Carolina, which enhances the potential of annamycin for treating pancreatic cancer. The upcoming Phase 3 MIRACLE trial data for relapsed/refractory acute myeloid leukemia and a Phase 1b/2 study for annamycin in pancreatic cancer further bolster the positive outlook for the company.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments